Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

1569 ARTÍCULOS , VIENDO DEL 1156 AL 1170

Reducing disability via a family centered intervention for acutely ill persons with Alzheimer's disease and related dementias: protocol of a cluster-randomized controlled trial (Fam-FFC study)

Boltz M, Kuzmik A, Resnick B, Trotta R, Mogle J, BeLue R, Leslie D, Galvin JE.

Trials. 2018 Sep 17;19(1):496. doi: 10.1186/s13063-018-2875-1.

The BACE-1 inhibitor CNP520 for prevention trials in Alzheimer's disease

Neumann U, Ufer M, Jacobson LH, Rouzade-Dominguez ML, Huledal G, Kolly C, Lüönd RM, Machauer R, Veenstra SJ, Hurth K, Rueeger H, Tintelnot-Blomley M, Staufenbiel M, Shimshek DR, Perrot L, Frieauff W, Dubost V, Schiller H, Vogg B, Beltz K, Avrameas A, Kretz S, Pezous N, Rondeau JM, Beckmann N, Hartmann A, Vormfelde S, David OJ, Galli B, Ramos R, Graf A, Lopez Lopez C.

EMBO Mol Med. 2018 Nov;10(11):e9316. doi: 10.15252/emmm.201809316.

Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer's disease (BLAZE)

Salloway S, Honigberg LA, Cho W, Ward M, Friesenhahn M, Brunstein F, Quartino A, Clayton D, Mortensen D, Bittner T, Ho C, Rabe C, Schauer SP, Wildsmith KR, Fuji RN, Suliman S, Reiman EM, Chen K, Paul R.

Alzheimers Res Ther. 2018 Sep 19;10(1):96. doi: 10.1186/s13195-018-0424-5.

Physical activity can improve cognition in patients with Alzheimer's disease: a systematic review and meta-analysis of randomized controlled trials

Du Z, Li Y, Li J, Zhou C, Li F, Yang X.

Clin Interv Aging. 2018 Sep 4;13:1593-1603. doi: 10.2147/CIA.S169565. eCollection 2018.

Chinese Medicine for Alzheimer's Disease: A Meta-Analysis of Randomized Controlled Trials

Ma HK, Liu Y, Li B, Zhang Y, Sun LJ, Xu FQ.

Chin J Integr Med. 2018 Dec;24(12):938-943. doi: 10.1007/s11655-018-2567-4. Epub 2018 Sep 22.

Donepezil-based multi-functional cholinesterase inhibitors for treatment of Alzheimer's disease

Li Q, He S, Chen Y, Feng F, Qu W, Sun H.

Eur J Med Chem. 2018 Oct 5;158:463-477. doi: 10.1016/j.ejmech.2018.09.031. Epub 2018 Sep 13.

DYRK1A kinase inhibition with emphasis on neurodegeneration: A comprehensive evolution story-cum-perspective

Pathak A, Rohilla A, Gupta T, Akhtar MJ, Haider MR, Sharma K, Haider K, Yar MS.

Eur J Med Chem. 2018 Oct 5;158:559-592. doi: 10.1016/j.ejmech.2018.08.093. Epub 2018 Sep 11.

An evaluation of memantine ER + donepezil for the treatment of Alzheimer's disease

Calhoun A, King C, Khoury R, Grossberg GT.

Expert Opin Pharmacother. 2018 Oct;19(15):1711-1717. doi: 10.1080/14656566.2018.1519022. Epub 2018 Sep 23.

Association between Neuropsychiatric Improvement and Neurocognitive Change in Alzheimer's Disease: Analysis of the CATIE-AD Study

Nagata T, Shinagawa S, Nakajima S, Mimura M, Shigeta M.

J Alzheimers Dis. 2018;66(1):139-148. doi: 10.3233/JAD-180304.

Nilvadipine in mild to moderate Alzheimer disease: A randomised controlled trial

Lawlor B, Segurado R, Kennelly S, Olde Rikkert MGM, Howard R, Pasquier F, Börjesson-Hanson A, Tsolaki M, Lucca U, Molloy DW, Coen R, Riepe MW, Kálmán J, Kenny RA, Cregg F, O'Dwyer S, Walsh C, Adams J, Banzi R, Breuilh L, Daly L, Hendrix S, Aisen P, Gaynor S, Sheikhi A, Taekema DG, Verhey FR, Nemni R, Nobili F, Franceschi M, Frisoni G, Zanetti O, Konsta A, Anastasios O, Nenopoulou S, Tsolaki-Tagaraki F, Pakaski M, Dereeper O, de la Sayette V, Sénéchal O, Lavenu I, Devendeville A, Calais G, Crawford F, Mullan M; NILVAD Study Group.

PLoS Med. 2018 Sep 24;15(9):e1002660. doi: 10.1371/journal.pmed.1002660. eCollection 2018 Sep.

Alzheimer's Disease: Special Focus on the Efficacy of Computer-Based Training Programs - A Mini-Review

Klimova B, Kuca K, Maresova P.

Curr Alzheimer Res. 2018;15(13):1213-1219. doi: 10.2174/1567205015666180925105902.

Global View on Alzheimer's Disease and Diabetes Mellitus: Threats, Risks and Treatment Alzheimer's Disease and Diabetes Mellitus

Klimova B, Kuca K, Maresova P.

Curr Alzheimer Res. 2018;15(14):1277-1282. doi: 10.2174/1567205015666180925110222.

Study partners: essential collaborators in discovering treatments for Alzheimer's disease

Largent EA, Karlawish J, Grill JD.

Alzheimers Res Ther. 2018 Sep 27;10(1):101. doi: 10.1186/s13195-018-0425-4.

Resveratrol and Alzheimer's disease. From molecular pathophysiology to clinical trials

Drygalski K, Fereniec E, Koryciński K, Chomentowski A, Kiełczewska A, Odrzygóźdź C, Modzelewska B.

Exp Gerontol. 2018 Nov;113:36-47. doi: 10.1016/j.exger.2018.09.019. Epub 2018 Sep 25.

Alzheimer's disease (AD) therapeutics - 2: Beyond amyloid - Re-defining AD and its causality to discover effective therapeutics

Mullane K, Williams M.

Biochem Pharmacol. 2018 Dec;158:376-401. doi: 10.1016/j.bcp.2018.09.027. Epub 2018 Sep 29.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias